Skip to content
DataLookout
Menu

NCT06606314

Specified Drug-use Surveillance of Fabhalta Capsules

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 14 with changes below, 1 re-verified with no change.

  1. Minor Trial completed
    • Primary completion date changed from estimate of Sep 30, 2028 to Oct 15, 2026
    • Study sites: 91 to 90
  2. Minor Site details revised at 66 of 91 sitesv14
  3. Minor Site details revised at 4 of 91 sitesv13
  4. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment increased: 100 → 132 participants
    • Study sites: 92 to 91
    v11
  5. Minor Study sites: 91 to 92v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study sites: 81 to 91v9
  2. Minor Study sites: 74 to 81v8
  3. Minor Study sites: 65 to 74v7
  4. Minor Study sites: 48 to 65v6
  5. Minor Study sites: 42 to 48v5
  6. Minor Study sites: 8 to 42
    • Start date: Sep 19, 2024 to Sep 18, 2024
    v4
  7. Minor Study sites: 1 to 8v3
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2024 to Sep 19, 2024
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Occurrence status of infections.
Timeframe: 48weeks

Secondary (3)

Occurrence status of serious hemolysis after discontinuation of Fabhalta.
Occurrence status of adverse events and adverse drug reactions.
Incidence of breakthrough hemolysis and change of hemolysis-related markers and status of red blood cell transfusion-free.

Sites

90 sites in 1 country